Fitness trade-offs associated with the evolution of resistance to antifungal drug combinations

Cell Reports

Volumn 10, Issue 5, 2015, Pages 809-819

  Hill, Jessica A ^a   O'Meara, Teresa R ^a   Cowen, Leah E ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN; ERG11 PROTEIN; FLUCONAZOLE; FUNGAL PROTEIN; GELDANAMYCIN; HEAT SHOCK PROTEIN 90; TAC1 PROTEIN; TACROLIMUS; UNCLASSIFIED DRUG; UPC2 PROTEIN;

ANTIFUNGAL RESISTANCE; ARTICLE; CANDIDA ALBICANS; CELL LINEAGE; CELL STRESS; CONTROLLED STUDY; DRUG EFFECT; FUNGAL GENETICS; FUNGAL STRAIN; FUNGAL VIRULENCE; FUNGUS FITNESS; IN VITRO STUDY; IN VIVO STUDY; MACROPHAGE; MICROBIOLOGICAL PARAMETERS; MOLECULAR EVOLUTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION;

CANDIDA ALBICANS;

EID: 84923353127     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2015.01.009     Document Type: Article

References (45)

1. Anderson J.B. Evolution of antifungal-drug resistance: mechanisms and pathogen fitness. Nat. Rev. Microbiol. 2005, 3:547-556.
2. Anderson J.B., Sirjusingh C., Parsons A.B., Boone C., Wickens C., Cowen L.E., Kohn L.M. Mode of selection and experimental evolution of antifungal drug resistance in Saccharomyces cerevisiae. Genetics 2003, 163:1287-1298.
3. Andersson D.I., Hughes D. Antibiotic resistance and its cost: is it possible to reverse resistance?. Nat. Rev. Microbiol. 2010, 8:260-271.
4. Andersson D.I., Hughes D. Persistence of antibiotic resistance in bacterial populations. FEMS Microbiol. Rev. 2011, 35:901-911.
5. Blankenship J.R., Singh N., Alexander B.D., Heitman J. Cryptococcus neoformans isolates from transplant recipients are not selected for resistance to calcineurin inhibitors by current immunosuppressive regimens. J.Clin. Microbiol. 2005, 43:464-467.
6. Chen G., Bradford W.D., Seidel C.W., Li R. Hsp90 stress potentiates rapid cellular adaptation through induction of aneuploidy. Nature 2012, 482:246-250.
7. Cooper V.S., Lenski R.E. The population genetics of ecological specialization in evolving Escherichia coli populations. Nature 2000, 407:736-739.
8. Coste A.T., Karababa M., Ischer F., Bille J., Sanglard D. TAC1, transcriptional activator of CDR genes, is a new transcription factor involved in the regulation of Candida albicans ABC transporters CDR1 and CDR2. Eukaryot. Cell 2004, 3:1639-1652.
9. Coste A., Selmecki A., Forche A., Diogo D., Bougnoux M.E., d'Enfert C., Berman J., Sanglard D. Genotypic evolution of azole resistance mechanisms in sequential Candida albicans isolates. Eukaryot. Cell 2007, 6:1889-1904.
10. Cowen L.E. Hsp90 orchestrates stress response signaling governing fungal drug resistance. PLoS Pathog. 2009, 5:e1000471.
11. Cowen L.E. The fungal Achilles' heel: targeting Hsp90 to cripple fungal pathogens. Curr. Opin. Microbiol. 2013, 16:377-384.
12. Cowen L.E., Lindquist S. Hsp90 potentiates the rapid evolution of new traits: drug resistance in diverse fungi. Science 2005, 309:2185-2189.
13. Cowen L.E., Singh S.D., Köhler J.R., Collins C., Zaas A.K., Schell W.A., Aziz H., Mylonakis E., Perfect J.R., Whitesell L., Lindquist S. Harnessing Hsp90 function as a powerful, broadly effective therapeutic strategy for fungal infectious disease. Proc. Natl. Acad. Sci. USA 2009, 106:2818-2823.
14. Desalermos A., Fuchs B.B., Mylonakis E. Selecting an invertebrate model host for the study of fungal pathogenesis. PLoS Pathog. 2012, 8:e1002451.
15. Forche A., Magee P.T., Selmecki A., Berman J., May G. Evolution in Candida albicans populations during a single passage through a mouse host. Genetics 2009, 182:799-811.
16. Fuchs B.B., O'Brien E., Khoury J.B., Mylonakis E. Methods for using Galleria mellonella as a model host to study fungal pathogenesis. Virulence 2010, 1:475-482.
17. Gagneux S., Long C.D., Small P.M., Van T., Schoolnik G.K., Bohannan B.J. The competitive cost of antibiotic resistance in Mycobacterium tuberculosis. Science 2006, 312:1944-1946.
18. Gow N.A., van de Veerdonk F.L., Brown A.J., Netea M.G. Candida albicans morphogenesis and host defence: discriminating invasion from colonization. Nat. Rev. Microbiol. 2012, 10:112-122.
19. Harrison B.D., Hashemi J., Bibi M., Pulver R., Bavli D., Nahmias Y., Wellington M., Sapiro G., Berman J. A tetraploid intermediate precedes aneuploid formation in yeasts exposed to fluconazole. PLoS Biol. 2014, 12:e1001815.
20. Hill J.A., Ammar R., Torti D., Nislow C., Cowen L.E. Genetic and genomic architecture of the evolution of resistance to antifungal drug combinations. PLoS Genet. 2013, 9:e1003390.
21. Hoot S.J., Smith A.R., Brown R.P., White T.C. An A643V amino acid substitution in Upc2p contributes to azole resistance in well-characterized clinical isolates of Candida albicans. Antimicrob. Agents Chemother. 2011, 55:940-942.
22. Lamb D.C., Kelly D.E., White T.C., Kelly S.L. The R467K amino acid substitution in Candida albicans sterol 14alpha-demethylase causes drugresistance through reduced affinity. Antimicrob. Agents Chemother. 2000, 44:63-67.
23. Lang G.I., Murray A.W., Botstein D. The cost of gene expression underlies a fitness trade-off in yeast. Proc. Natl. Acad. Sci. USA 2009, 106:5755-5760.
24. Laxminarayan R., Duse A., Wattal C., Zaidi A.K., Wertheim H.F., Sumpradit N., Vlieghe E., Hara G.L., Gould I.M., Goossens H., et al. Antibiotic resistance-the need for global solutions. Lancet Infect. Dis. 2013, 13:1057-1098.
25. MacCallum D.M., Odds F.C. Temporal events in the intravenous challenge model for experimental Candida albicans infections in female mice. Mycoses 2005, 48:151-161.
26. MacLean R.C., Hall A.R., Perron G.G., Buckling A. The population genetics of antibiotic resistance: integrating molecular mechanisms and treatment contexts. Nat. Rev. Genet. 2010, 11:405-414.
27. New A.M., Cerulus B., Govers S.K., Perez-Samper G., Zhu B., Boogmans S., Xavier J.B., Verstrepen K.J. Different levels of catabolite repression optimize growth in stable and variable environments. PLoS Biol. 2014, 12:e1001764.
28. Palmer A.C., Kishony R. Understanding, predicting and manipulating the genotypic evolution of antibiotic resistance. Nat. Rev. Genet. 2013, 14:243-248.
29. Pavelka N., Rancati G., Zhu J., Bradford W.D., Saraf A., Florens L., Sanderson B.W., Hattem G.L., Li R. Aneuploidy confers quantitative proteome changes and phenotypic variation in budding yeast. Nature 2010, 468:321-325.
30. Paya C.V. Fungal infections in solid-organ transplantation. Clin. Infect. Dis. 1993, 16:677-688.
31. Pfaller M.A., Diekema D.J. Epidemiology of invasive mycoses in North America. Crit. Rev. Microbiol. 2010, 36:1-53.
32. Poláková S., Blume C., Zárate J.A., Mentel M., Jørck-Ramberg D., Stenderup J., Piskur J. Formation of new chromosomes as a virulence mechanism in yeast Candida glabrata. Proc. Natl. Acad. Sci. USA 2009, 106:2688-2693.
33. Reedy J.L., Husain S., Ison M., Pruett T.L., Singh N., Heitman J. Immunotherapy with tacrolimus (FK506) does not select for resistance to calcineurin inhibitors in Candida albicans isolates from liver transplant patients. Antimicrob. Agents Chemother. 2006, 50:1573-1577.
34. Schulz zur Wiesch P., Engelstädter J., Bonhoeffer S. Compensation of fitness costs and reversibility of antibiotic resistance mutations. Antimicrob. Agents Chemother. 2010, 54:2085-2095.
35. Selmecki A., Forche A., Berman J. Aneuploidy and isochromosome formation in drug-resistant Candida albicans. Science 2006, 313:367-370.
36. Selmecki A.M., Dulmage K., Cowen L.E., Anderson J.B., Berman J. Acquisition of aneuploidy provides increased fitness during the evolution of antifungal drug resistance. PLoS Genet. 2009, 5:e1000705.
37. Shapiro R.S., Uppuluri P., Zaas A.K., Collins C., Senn H., Perfect J.R., Heitman J., Cowen L.E. Hsp90 orchestrates temperature-dependent Candida albicans morphogenesis via Ras1-PKA signaling. Curr. Biol. 2009, 19:621-629.
38. Shapiro R.S., Robbins N., Cowen L.E. Regulatory circuitry governing fungal development, drug resistance, and disease. Microbiol. Mol. Biol. Rev. 2011, 75:213-267.
39. Shapiro R.S., Sellam A., Tebbji F., Whiteway M., Nantel A., Cowen L.E. Pho85, Pcl1, and Hms1 signaling governs Candida albicans morphogenesis induced by high temperature or Hsp90 compromise. Curr. Biol. 2012, 22:461-470.
40. Singh S.D., Robbins N., Zaas A.K., Schell W.A., Perfect J.R., Cowen L.E. Hsp90 governs echinocandin resistance in the pathogenic yeast Candida albicans via calcineurin. PLoS Pathog. 2009, 5:e1000532.
41. Singh-Babak S.D., Babak T., Diezmann S., Hill J.A., Xie J.L., Chen Y.L., Poutanen S.M., Rennie R.P., Heitman J., Cowen L.E. Global analysis of the evolution and mechanism of echinocandin resistance in Candida glabrata. PLoS Pathog. 2012, 8:e1002718.
42. Travisano M., Lenski R.E. Long-term experimental evolution in Escherichia coli. IV. Targets of selection and the specificity of adaptation. Genetics 1996, 143:15-26.
43. Vincent B.M., Lancaster A.K., Scherz-Shouval R., Whitesell L., Lindquist S. Fitness trade-offs restrict the evolution of resistance to amphotericin B. PLoS Biol. 2013, 11:e1001692.
44. White T.C. Increased mRNA levels of ERG16, CDR, and MDR1 correlate with increases in azole resistance in Candida albicans isolates from a patient infected with human immunodeficiency virus. Antimicrob. Agents Chemother. 1997, 41:1482-1487.
45. White T.C., Pfaller M.A., Rinaldi M.G., Smith J., Redding S.W. Stable azole drug resistance associated with a substrain of Candida albicans from an HIV-infected patient. Oral Dis. 1997, 3(Suppl 1):S102-S109.